ASMB (Assembly Corp) Future Price to Earnings

Symbol and logo of brand Assembly Biosciences, Inc. (ASMB)

The Assembly Biosciences (ASMB) price chart reflects the performance of a company developing innovative liver disease therapies, where the key metric is recorded at 0.00. Assets are shielded from external trade conflicts and sanctions due to the localization of R&D in the US. However, the business faces intense pressure from market behemoths in the struggle for leadership in the functional cure segment for chronic hepatitis B.

ASMB - Assembly Bio Market Cap to Projected Earnings over the range 07/04/2022 - 11/10/2026

Summary analytical data breakdowns for Assembly Corp (ASMB)

- current price and projected stock value:
Stock Quotes Assembly Biosciences, Inc.|ASMB - Fair Value Consensus
- business market valuation indicators:
Market Value Assembly Bio|ASMB - Total Company Value
- balance sheet equity data:
Book Value per Share Assembly Biosciences|ASMB - Book Valuation of Business|Market Cap to Net Assets Ratio assemblybio.com|ASMB - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Assembly Biosciences|ASMB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Assembly Biosciences|ASMB - Aggregate Debt Obligations|Debts to Book Capitalization Assembly Bio|ASMB - Company Long-Term Debts|Company Short-Term Debt Assembly Biosciences|Quick Liquidity assemblybio.com
- earnings and market ratios statistics:
ASMB - Net Financial Result|Projected Future Earnings Assembly Biosciences|ASMB - Market Cap to Earnings|Future Price to Earnings Assembly Biosciences Inc|ASMB - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Assembly Bio|ASMB - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Assembly Biosciences|ASMB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months assemblybio.com|ASMB - Earnings per share growth rate in current year|Expected earnings per share growth for next year Assembly Biosciences
Fundamental valuation:Assembly Biosciences, Inc.
Brand item of Assembly Biosciences

Forward P/E is calculated by dividing market capitalization by projected annual earnings. This indicator serves as a tool for valuing a business relative to its expected returns. For Assembly Biosciences (ASMB), this parameter reflects the market's bet on the success of innovative capsid inhibitors. The issuer's expected P/E allows for a comparison of current quotes with the potential of hepatitis B therapy. The trend of the curve signals the degree of asset overvaluation.

Analysis of competing companies

Projected Price to Earnings ARWR (Arrowhead Pharmaceuticals, Inc.)|MIRM (Mirum Pharmaceuticals, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings dynavax.com DVAX|Tekmira Pharmaceuticals - Future Price to Earnings|Inventiva S.A. - Forward P/E Multiple|Market Cap to Projected Earnings gyretx.com GYRE|GALT (galectintherapeutics.com) - Projected Price to Earnings|GNFT (GENFIT) - Future Price to Earnings|DRRX (DURECT Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Aligos ALGS|Future Price to Earnings BioVie Inc. (BIVI)|GLMD (galmedpharma.com) - Future Price to Earnings Multiple|Forward P/E Multiple NDRA (ENDRA Life Sciences Inc.)|Forward P/E Multiple Hepion Pharmaceuticals Inc. HEPA